A real-world comparison of nivolumab plus cabozantinib and pembrolizumab plus lenvatinib focusing on safety outcomes in metastatic renal cell carcinoma: results from the JK-FOOT consortium. - Yanagisawa T; Mori K; Kawada T; Katayama S; Tsujino T; Maenosono R; Toyoda S; Nukaya T; Morinaka H; Tamura K; Fukuokaya W; Urabe F; et al. (Cancer immunology, immunotherapy : CII, 2026)